192 related articles for article (PubMed ID: 15375544)
1. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
[TBL] [Abstract][Full Text] [Related]
2. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling.
Mao Y; Wu J; Skog S; Eriksson S; Zhao Y; Zhou J; He Q
Oncol Rep; 2005 May; 13(5):837-46. PubMed ID: 15809747
[TBL] [Abstract][Full Text] [Related]
3. A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma.
Wu J; Mao Y; He L; Wang N; Wu C; He Q; Skog S
Anticancer Res; 2000; 20(6C):4815-20. PubMed ID: 11205225
[TBL] [Abstract][Full Text] [Related]
4. Breast tumour thymidine kinase levels and disease recurrence.
O'Neill KL; McKelvey VJ; Hoper M; Monteverde H; Odling-Smee GW; Logan H; Abram WP; McKenna PG
Med Lab Sci; 1992 Dec; 49(4):244-7. PubMed ID: 1339926
[TBL] [Abstract][Full Text] [Related]
5. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
6. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase in malignant melanoma.
Borovanský J; Stríbrná J; Elleder M; Netíková I
Melanoma Res; 1994 Oct; 4(5):275-9. PubMed ID: 7858409
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.
He Q; Skog S; Wang N; Eriksson S; Tribukait B
Eur J Cell Biol; 1996 Jun; 70(2):117-24. PubMed ID: 8793383
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management.
Guan H; Sun Y; Zan Q; Xu M; Li Y; Zhou J; He E; Eriksson S; Wen W; Skog S
Mol Med Rep; 2009; 2(6):923-9. PubMed ID: 21475922
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical assessment of proliferation rate of breast carcinoma cells using Ki-67, MIB-1 and anti-PCNA monoclonal antibodies.
Markiewski M; Domagała W
Pol J Pathol; 1996; 47(4):189-94. PubMed ID: 9097711
[TBL] [Abstract][Full Text] [Related]
11. Tumor markers in stage P1 bladder cancer.
Stavropoulos NE; Ioachim E; Charchanti A; Michael MC; Kitsiou E; Mihailidis I; Hastazeris K; Agnantis NJ
Anticancer Res; 2001; 21(2B):1495-8. PubMed ID: 11396238
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
13. A 65 kDa oncofetal protein (p65), proliferating cell nuclear antigen (PCNA) and Ki67 expression in breast cancer patients.
Niewiadomska H; Mirowski M; Stempien M; Olborski B; Blonski JZ; Hanausek M; Wierzbicki R
Neoplasma; 1998; 45(4):216-22. PubMed ID: 9890664
[TBL] [Abstract][Full Text] [Related]
14. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
[TBL] [Abstract][Full Text] [Related]
15. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer.
Mao Y; Wu J; Wang N; He L; Wu C; He Q; Skog S
Cancer Invest; 2002; 20(7-8):922-31. PubMed ID: 12449723
[TBL] [Abstract][Full Text] [Related]
16. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
17. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of proliferating markers Ki-67, PCNA in gastric cancers.
Czyzewska J; Guzińska-Ustymowicz K; Lebelt A; Zalewski B; Kemona A
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():64-6. PubMed ID: 15638377
[TBL] [Abstract][Full Text] [Related]
19. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.
Wang J; Liu Q; Zhou X; He Y; Guo Q; Shi Q; Eriksson S; Zhou J; He E; Skog S
Tumour Biol; 2017 Jun; 39(6):1010428317706479. PubMed ID: 28651488
[TBL] [Abstract][Full Text] [Related]
20. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M
Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
